Ophthalmic Drugs Conference

by Stephen Riddle

SAE Media Group’s 5th Annual
Ophthalmic Drugs Conference
21 – 22 November 2022 | London, UK

Delving into advanced R&D and Delivery of Ocular Therapeutics

SAE Media Group’s 5th Annual Ophthalmic Drugs Conference will explore advancements in ophthalmic treatments and variety of novel drugs, which are showing good clinical trial data. Drug delivery will also be an important aspect of the agenda, with advancements in novel technologies. Further key areas will be gene therapy and Artificial Intelligence with developments on the latest drug pipelines and clinical trials.

Benefits of Attending:

•Assess new industry directions through the latest data from ophthalmic clinical trials
•Review advanced techniques in treating age-related diseases of ophthalmology
•Explore evolving therapeutic potential in undruggable diseases through innovative gene therapies
•Examine novel methodologies in delivery technologies being used to further the ophthalmic therapeutic field
•Engage in the regulatory landscape of ophthalmic drugs and key considerations for R&D

Delegates will have the opportunity to network with the following companies:

•Aerie Pharmaceuticals

And many more!

Who Should Attend:

•CEOs, CMOs and Researchers from pharmaceutical companies involved in ocular drug development, in addition to biotechnologies involved in ocular drug delivery research.
•Heads and VPs of Retinal Health, Ocular Therapy, Medical Safety, and Ophthalmology.
•Professors, Senior Lecturers, and Specialists in Ocular biology and immunology, and clinical pharmaceuticals.

The two-day conference will bring you high-quality insights and industry connections on the latest advances in ocular drug design and delivery, and a platform for exchanging ideas.

Early Bird Offers:
•Register by 30th September to save £100

For more information contact:
Nikisha Galoria | Marketing Executive | SAE Media Group
Email: [email protected]
Phone: +44 (0) 20 7827 6164

Follow us on:
LinkedIn: SAE Media Group Pharma
Twitter: @SAEMGPharma

This post was originally published on Source Link

You may also like